Skip to Content

ArmonAir RespiClick Approval History

FDA Approved: Yes (First approved January 27, 2017)
Brand name: ArmonAir RespiClick
Generic name: fluticasone propionate
Dosage form: Inhalation Powder
Company: Teva Pharmaceuticals USA, Inc.
Treatment for: Asthma, Maintenance

ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma.

Development History and FDA Approval Process for ArmonAir RespiClick

DateArticle
Jan 31, 2017Approval Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide